Anteris Technologies Ltd (AVR)
20mins delayed
Movement
1 Year Return
Anteris Technologies Ltd Chart
| Share price | |
| Last | |
| Change | |
| Volume | |
| Turnover | |
| Market Cap | $36.05 million |
| Today's Movement | |
| Prev. Close | |
| Open | |
| Day Range | - |
| VWAP | |
| Historical Stats | |
| 52w Range | - |
| 4w Avg Volume | |
| 4w Avg Turnover | |
| (delayed) | |
AVR Statistics
02 June
1,157 / 2,239
ASX Size Rank
1yr Return
vs Sector (1yr)
-27.79%
vs ASX 200 (1yr)
+9.35%
$36.05 million
Market Cap
Share Issue
5.91 million
All Ords (%)
N/A
Short Sold
0%
Current Fundamentals
02 June
N/A
PE Ratio
EPS ($)
-0.99
Earnings Yield
-16.23%
NTA ($)
2.10
N/A
Dividend Yield
DPS ($)
-
Gross Div. Yield
-
Gross DPS ($)
-
Company Overview
Anteris Technologies Ltd (AVR, formerly Admedus Ltd) is a structural heart company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Its focus is on investing in and developing next generation technologies with world class partners and acquiring strategic assets to grow product and service offerings.
Former Names
bioMD Limited (BOD), 30/06/2011; Allied Healthcare Group Ltd, 22/11/2013; Admedus Ltd (AHZ), 21/05/2020
Upcoming Calendar
| 21 Aug 2020 | Report (Interim) |
| 26 Feb 2021 | Report (Prelim) |
| 8 Apr 2021 | Report (Annual) |
Dividend History
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| No dividends paid in the last 5 years | ||||
See Upcoming Dividends for all ASX companies.
Announcements
| Date | Heading | Pages | File Size | Time |
|---|---|---|---|---|
Broker Consensus
The buy, hold and sell recommendations from Australian stockbroking firms are combined to form a "broker consensus". See the Consensus Data posts for more information.
AVR is not covered by a major broker,
or data from most recent compilation was omitted due
to not meeting QA guidelines.
Directors & Management
| Name | Title | Since | Bio |
|---|---|---|---|
| Mr Stephen (Steve) Denaro | Company Secretary, Non-Executive Director | Oct 2018 |
|
| Mr John Seaberg | Non-Executive Director, Non-Executive Chairman | Oct 2014 |
|
| Mr Wayne Paterson | Managing Director, Chief Executive Officer | Feb 2016 |
|
| Dr Wenyi Gu | Non-Executive Director | Oct 2018 |
|
| Dr Yanheng Wu | Non-Executive Director | Dec 2018 |
|
| Matthew McDonnell | Chief Financial Officer | N/A | |
| Kiran Bhirangi | Chief Medical Officer | N/A | |
| David St Denis | Chief Operating Officer | N/A | |
| Martha Engel | General Counsel | N/A |
Director Transactions
AVR directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
| Date | Director | Type | Amount | Price | Value | Notes |
|---|---|---|---|---|---|---|
| 20/03/20 | Stephen (Steve) Denaro | Issued | 25,000 | $3.500 | $87,500 | Issue of options. |
| 20/03/20 | John Seaberg | Issued | 60,000 | $3.500 | $210,000 | Issue of options. |
| 20/03/20 | Wayne Paterson | Issued | 350,000 | $3.500 | $1,225,000 | Issue of options. |
Shareholder Distribution
| Holding Size | 1 - 1,000 | 1,001 - 5,000 | 5,001 - 10,000 | 10,001 - 100,000 | 100,001 and over | Total Shareholders |
|---|---|---|---|---|---|---|
| No. of Shareholders | 5,647 | 411 | 72 | 41 | 7 | 6,178 |
Top 20 Shareholders
| Name | Shares | Capital |
|---|---|---|
| Constellation Intl Holdings Limited | 730,192 | 12.35% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 652,219 | 11.04% |
| Constellation Immunotherapy Limited | 402,093 | 6.80% |
| National Nominees Limited |
373,228 | 6.31% |
| HSBC Custody Nominees (Australia) Limited Gsco Eca | 290,293 | 4.91% |
| Star Bright Holding Limited | 173,680 | 2.94% |
| Merrill Lynch (Australia) Nominees Pty Limited |
169,733 | 2.87% |
| J P Morgan Nominees Australia Pty Limited | 87,768 | 1.48% |
| Citicorp Nominees Pty Limited | 84,369 | 1.43% |
| Mr Patrick Chew | 73,670 | 1.25% |
| Dr Abdul Ahad Khan | 36,895 | 0.62% |
| Mr Daniel Bernard Clough | 33,584 | 0.57% |
| Through2 Investments Pty Ltd |
33,000 | 0.56% |
| Mr Roger Anthony Pierce | 32,673 | 0.55% |
| Bulldog Shale Pty Ltd |
30,000 | 0.51% |
| Carron Services Limited | 28,572 | 0.48% |
| Mr Joseph John Doyle and Mrs Cheryl Anne Doyle | 23,527 | 0.40% |
| Mr Athanasios Farmakis | 23,000 | 0.39% |
| Zcsf Nominees Pty Ltd |
20,505 | 0.35% |
| Mr Dale Anthony Reed | 20,000 | 0.34% |
| Appwam Pty Ltd | 20,000 | 0.34% |
| Mrs Janet Louise Bowtell and Mr Gary Owen Bowtell |
20,000 | 0.34% |
| All other shareholders | 43.17 % | |
The Top 20 Shareholders of AVR hold 56.83% of shares on issue.
AVR Share Price History
| Date | Close | Change | % Change | Open | High | Low | Volume | Turnover |
|---|---|---|---|---|---|---|---|---|
AVR Historical Data
Download up to 20 years of share price history.
| Year | Closing Price (30 June) | Last Trade |
|---|
Offical data as published by ASX. See more Data Downloads.
Company Details
Principal Activity: Sale, distribution, maintenance and implementation of infusion solutions to major hospitals and health facilities in Australia and New Zealand; The manufacturing, sale and distribution of proprietary ADAPT regenerative tissue products globally; and Continued research and development of regenerative medicine and immunotherapies.
Incorporated: bioMD Limited was incorporated in June 1999 in Western Australia. Code changed to Allied Healthcare Group Ltd (AHZ) on 30/06/2011
Suite 302, Level 3, Toowong Tower, 9 Sherwood Rd
Toowong QLD 4066
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.